Biocytogen and CtM Biotech Identify Tri-Specific T Cell Engager for Cancers

Biocytogen Pharma (Beijing) and CtM Biotech (Shanghai), a division of Lepu Biopharma, reported that their tri-specific T cell engager for an intracellular target showed preclinical anti-tumor activity for both hematological malignancies and solid tumors. In just one year of collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) that includes a T co-stimulatory signal for a WT1-targeting T cell engager, which the companies believe will prove to be best-in-class and first-in-class. WT1 (Wilms’ tumor gene 1) is an intracellular protein highly enriched in the cells of certain cancers. More details....

Stock Symbol: (HK: 02315)

Share this with colleagues: